Equities
Health CarePharmaceuticals & Biotechnology
  • Price (IDR)1,585.00
  • Today's Change15.00 / 0.96%
  • Shares traded29.40m
  • 1 Year change27.31%
  • Beta1.0836
Data delayed at least 10 minutes, as of Dec 08 2016 09:10 GMT.
More ▼

Forecasts data is unavailable for this security.

Consensus recommendation

As of Dec 06, 2016, the consensus forecast amongst 17 polled investment analysts covering Kalbe Farma Tbk PT advises investors to hold their position in the company. This has been the consensus forecast since the sentiment of investment analysts deteriorated on May 02, 2016. The previous consensus forecast advised that Kalbe Farma Tbk PT would outperform the market.
  • 1yr ago
  • 3M ago
  • 2M ago
  • 1M ago
  • Latest
Select bar for recommendation details.
RecommendationsLatest
Buy5
Outperform3
Hold4
Underperform4
Sell1

Share price forecast

The 17 analysts offering 12 month price targets for Kalbe Farma Tbk PT have a median target of 1,620.00, with a high estimate of 2,200.00 and a low estimate of 1,250.00. The median estimate represents a 2.21% increase from the last price of 1,585.00.
High38.8%2,200.00
Med2.2%1,620.00
Low-21.1%1,250.00

Dividends

In 2015, Kalbe Farma Tbk PT reported a dividend of 19.00 IDR, equaling last years dividend. The 13 analysts covering the company expect dividends of 22.01 IDR for the upcoming fiscal year, an increase of 15.83%.
Div growth (TTM)0.00%
More ▼

Earnings history & estimates

On Oct 31, 2016, Kalbe Farma Tbk PT reported 3rd quarter 2016 earnings of 11.87 per share. This result exceeded the 10.78 expectation of the one analyst covering the company and exceeded last year's 3rd quarter results by 27.60%.
The next earnings announcement is expected on Mar 29, 2017.
Average growth rate+0.91%
Kalbe Farma Tbk PT reported annual 2015 earnings of 42.76 per share on Feb 26, 2016.
The next earnings announcement from Kalbe Farma Tbk PT is expected the week of Mar 29, 2017.
Average growth rate+8.10%
More ▼

Revenue history & estimates

PT Kalbe Farma Tbk. had 3rd quarter 2016 revenues of 4.82bn. This bettered the 4.78bn estimate of the one analyst covering the company. This was 9.35% above the prior year's 3rd quarter results.
Average growth rate+2.47%
PT Kalbe Farma Tbk. had revenues for the full year 2015 of 17.89bn. This was 2.99% above the prior year's results.
Average growth rate+13.46%
More ▼
© Thomson Reuters Click for restrictions
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.